Education
About Us
Working with TipRanks
Follow Us
OncoSil Medical Ltd (AU:OSL)
ASX:OSL
OSL Stock Chart & Stats
AU$0.97
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.97
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.62 - AU$2.08
Previous CloseN/A
Volume350.23K
Average Volume (3M)24.03K
Market Cap
AU$14.88M
Enterprise ValueAU$8.93M
Total Cash (Recent Filing)AU$2.85M
Total Debt (Recent Filing)AU$42.47K
Price to Earnings (P/E)―
Beta0.56
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding23,615,334
10 Day Avg. Volume8,764
30 Day Avg. Volume24,029
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)4.23
Price to Sales (P/S)11.20
P/FCF Ratio-1.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Specialized Clinical ProductOncoSil’s device is a focused, clinically-oriented therapy for locally advanced pancreatic cancer delivered via EUS-guided brachytherapy. This specialization creates clinical and technical barriers to entry, supporting durable differentiation and a focused addressable market for sustained adoption.
Low LeverageA debt-to-equity ratio of 0.0225 indicates minimal financial leverage, lowering refinancing and interest-service risk. This balance sheet flexibility is a durable strength, enabling continued investment in clinical programs and commercialization without immediate debt pressure.
Top-line GrowthReported revenue growth of ~31.85% demonstrates commercial traction and growing market acceptance of the product. Sustained top-line momentum can enable scale economics, absorb fixed R&D and commercial costs, and create a clearer path to improving margins over the medium term.
Bears Say
Persistent UnprofitabilityDeeply negative gross, net, EBIT and EBITDA margins indicate the company is not generating profitable unit economics. Persistent unprofitability points to structural cost or pricing issues that must be resolved for long-term sustainability, increasing dependence on external funding.
Negative Cash FlowNegative operating and free cash flows signal ongoing cash burn and limited internal funding capacity. This creates a durable financing need that can lead to dilution or constrained investment in trials, regulatory work, and commercialization if external capital is not secured.
Very Small Internal TeamAn employee count of two indicates a very small in-house team, limiting capacity for clinical operations, regulatory submissions, and commercial scaling. Reliance on partners or contractors increases execution risk and can slow sustained market expansion over the medium term.
OncoSil Medical Ltd News
OSL FAQ
What was OncoSil Medical Ltd’s price range in the past 12 months?
OncoSil Medical Ltd lowest share price was AU$0.62 and its highest was AU$2.08 in the past 12 months.
What is OncoSil Medical Ltd’s market cap?
OncoSil Medical Ltd’s market cap is AU$14.88M.
When is OncoSil Medical Ltd’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were OncoSil Medical Ltd’s earnings last quarter?
Currently, no data Available
Is OncoSil Medical Ltd overvalued?
According to Wall Street analysts OncoSil Medical Ltd’s price is currently Overvalued.
Does OncoSil Medical Ltd pay dividends?
OncoSil Medical Ltd does not currently pay dividends.
What is OncoSil Medical Ltd’s EPS estimate?
OncoSil Medical Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OncoSil Medical Ltd have?
OncoSil Medical Ltd has 23,615,334 shares outstanding.
What happened to OncoSil Medical Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of OncoSil Medical Ltd?
Currently, no hedge funds are holding shares in AU:OSL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OncoSil Medical Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
―
20 days / 200 days
Momentum
-67.40%
12-Months-Change
Fundamentals
Return on Equity
-385.20%
Trailing 12-Months
Asset Growth
6.40%
Trailing 12-Months
Company Description
OncoSil Medical Ltd
OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in worldwide. Its lead product is OncoSil, a brachytherapy device indicated for the treatment of patients with locally advanced unresectable pancreatic cancer, in combination with gemcitabine-based chemotherapy. The company was formerly known as NeuroDiscovery Limited and changed its name to OncoSil Medical Limited in May 2013. OncoSil Medical Limited was incorporated in 2005 and is headquartered in North Sydney, Australia.
Technical Analysis
Cyclopharm Limited
―
Micro-X Ltd.
―
EMvision Medical Devices Ltd.
―
Control Bionics Ltd.
―
4DMedical Ltd
―